NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain, according to a press release.
NanoViricides emphasized NV-387’s proposed mechanism targeting viral cell attachment pathways common across filoviruses, positioning the candidate as a potential pandemic preparedness tool for Ebola and related viral threats. The company’s lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for respiratory viral infections such as RSV, COVID-19, Long COVID, influenza, as well as MPOX/smallpox and measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
The press release also notes that NanoViricides holds a worldwide exclusive perpetual license to its platform technology for several drugs targeting specific human viral diseases, including Ebola/Marburg viruses. The company’s nanoviricide class of drug candidates is based on intellectual property and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs for all antiviral infections.
The Ebola outbreak in Uganda and the DRC has renewed focus on the need for effective treatments. NV-387, if successful in clinical development, could provide an oral treatment option that is easier to administer than current injectable therapies. The company’s technology targets viral attachment, which could potentially be effective against multiple filovirus strains, including the Bundibugyo strain.
NanoViricides also has other drug candidates, including NV-CoV-2 for COVID-19 and NV-CoV-2-R, which encapsulates remdesivir. The company believes that since remdesivir is already FDA-approved, its drug candidate encapsulating remdesivir is likely to be approvable if safety is comparable.
As with any drug development, there are risks. The company notes that the path to drug development is lengthy and requires substantial capital, and there is no assurance that any of its candidates will show sufficient effectiveness and safety for human clinical development. For more information, the full press release is available at https://ibn.fm/mm3Z5.
